Pneuma is a med-tech and pharmaceutical company focused on the advancement of inhaled respiratory therapeutics. With a bold vision, advanced aerosol technology, and strategic partnerships, Pneuma brings new approaches and innovations to respiratory health that will significantly improve the existing standard-of-care and produce a positive impact on the health and well-being of the global community.

We focus our intellectual and financial capital on the illnesses and chronic health problems that come from smoking and smoking-related illnesses. Our treatments under development target smoking cessation, chronic obstructive pulmonary disease (COPD), non-small cell lung cancer (NSCLC), and reduced-risk nicotine (exclusively licensed to global consumer products company).

The Pneuma team is composed of former executives from Merck, Bayer, and Boehringer Ingelheim. Our Medical Advisors are academic thought leaders in pulmonary medicine at leading medical research centers.